Its own placebo-controlled trial: the placebo group improved about as much.
BioCopper1 is a copper–niacin compound sold by MitoSynergy. Its press release cites a double-blind trial as proof: “a 36% increase in ATP production” and “a 34% reduction in fatigue after 28 days”.
Short answer: we found the trial’s results posted on ClinicalTrials.gov. ATP rose 36% on the product — and 22% on the placebo capsules, and the difference between the two groups was not significant. On the main symptom score, the placebo group improved slightly more. It was a company-paid trial of 56 people with nerve or muscle pain, run in 2014 and, as far as we can find, never published in a journal.
BioCopper1 (copper–niacin, MitoSynergy) · evidence checked 2026-10-25
Grades are calculated from the studies listed, by fixed rules.
In a dish, it changed how skin cells from autistic children used oxygen — differently from cells of other children. That is a lab finding about cells, not a result in people. The company supplied the compound and part of the funding.
“Feeling tired all day. Coffee doesn't fix it anymore. You just feel wired and still exhausted. Try this.”
MitoSynergy · Facebook ad, seen Oct 2026
In the company’s own double-blind trial, ATP in blood platelets rose 36% on the product and 22% on the placebo capsules. The difference between the two groups was not statistically significant. The 36% compares the product group with itself.
On the trial’s main symptom score, people improved by about the same amount on placebo (25%) as on the product (22%); the posted results compare each group only with itself. A secondary score of chores and symptoms favoured the product. The trial was in people with nerve or muscle pain, not in tired, healthy coffee drinkers.
We found no study comparing how well people absorb this form with ordinary copper supplements. Most people get enough copper from food; too much copper is harmful.
Related: Magic Mind · mushroom coffees · mitochondria supplements